0001209191-24-005154.txt : 20240401
0001209191-24-005154.hdr.sgml : 20240401
20240401190013
ACCESSION NUMBER: 0001209191-24-005154
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240328
FILED AS OF DATE: 20240401
DATE AS OF CHANGE: 20240401
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wills Robert James
CENTRAL INDEX KEY: 0001634189
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50549
FILM NUMBER: 24811670
MAIL ADDRESS:
STREET 1: 175 TOYOTA PLAZA, 7TH FLOOR
CITY: MEMPHIS
STATE: TN
ZIP: 38103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oncternal Therapeutics, Inc.
CENTRAL INDEX KEY: 0001260990
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 621715807
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12230 EL CAMINO REAL
STREET 2: SUITE 230
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 434-1113
MAIL ADDRESS:
STREET 1: 12230 EL CAMINO REAL
STREET 2: SUITE 230
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: GTX INC /DE/
DATE OF NAME CHANGE: 20030822
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-03-28
0
0001260990
Oncternal Therapeutics, Inc.
ONCT
0001634189
Wills Robert James
12230 EL CAMINO REAL, SUITE 230
SAN DIEGO
CA
92130
1
0
0
0
0
Common Stock
2024-03-28
4
P
0
6914
8.4759
A
6914
D
The Reporting Person's common stock purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 980 shares at a weighted average price per share of $8.1548, with the sale of 980 shares of common stock at a price per share of $9.04 on February 23, 2024. The Reporting Person has agreed to pay the issuer $867.51, representing the full amount of the profit realized in connection with the short-swing transaction.
The reported price is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $8.095 to $9.00. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the range set forth above.
/s/Chase C. Leavitt, Attorney-in-fact
2024-04-01